Assetmark Inc. Acquires 2,658 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Assetmark Inc. increased its holdings in Regeneron Pharmaceuticals by 2.6%, bringing its total shares owned to 103,633, valued at approximately $65.7 million.
• Several institutional investors have shown significant interest in Regeneron, with Capital International Investors boosting its stake by 41.6% in the last quarter.
• Despite fluctuations in share ratings, analysts maintain a consensus of "Moderate Buy" for Regeneron Pharmaceuticals, with a projected price target averaging around $837.61.

Assetmark Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,633 shares of the biopharmaceutical company's stock after buying an additional 2,658 shares during the period. Assetmark Inc. owned about 0.09% of Regeneron Pharmaceuticals worth $65,727,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in REGN. Capital International Investors lifted its position in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Geode Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox increased its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after acquiring an additional 149,124 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on REGN. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a "neutral" rating in a research note on Friday, July 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $837.61.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $1.54 on Friday, reaching $563.10. The company's stock had a trading volume of 755,785 shares, compared to its average volume of 906,903. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The stock has a market capitalization of $60.79 billion, a P/E ratio of 14.34, a PEG ratio of 2.11 and a beta of 0.33. The stock's 50 day simple moving average is $542.56 and its two-hundred day simple moving average is $609.57.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the prior year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.